Affiliation:
1. Seoul National University Hospital
2. Seoul National University Hospital, Seoul national University College of medicine
Abstract
Abstract
Background: Clear cell papillary renal cell tumor (CCPRCT) was first reported in 2006 a patient with end stage renal disease. After that it was discovered in the kidney without end stage renal disease in the 2010s and started to be mentioned in pathology and urology. The incidence of CCPRCT is low and most of it is discovered incidentally, so there is a lack of reports on clinical characteristics and surgical outcome.
Methods: This study used clinical data from the Seoul National University Prospectively Enrolled Registry for Renal Cell Carcinoma-Nephrectomy (SUPER-RCC-Nx). Between August 2016 and July 2022, patients who underwent radical or partial nephrectomy with clear cell papillary RCC with pathological finding were included in this study. All patients’ pathologic reports were reviewed by 1 pathologist. Clinical characteristics and surgical outcomes were presented through descriptive statistics, and Kaplan-Meier curve used for survival analysis.
Results: Of the 2057 patients, CCPRCT was reported in 36 patients (1.8%). The median follow up period was 26.8 months. The median age was 67 years, and there were 10 females and 26 males. The median tumor size was 1.2 cm. Twenty-nine patients underwent partial nephrectomy. Seven patients with end-stage renal disease underwent radical nephrectomy. The median operative time for patients who underwent partial nephrectomy was 97.5 minutes and the estimated blood loss was 100 cc. The median hospital days was 4 and 30-day complications were 2 cases with clavien-dindo classification III or higher. During the follow-up period, there was no recurrence and cancer specific mortality.
Conclusions: The size of CCPRCT was small and there was no advanced stage at that time of diagnosis. There was no recurrence or cancer specific mortality during the follow-up period. A multi-center study with a large scale is needed in the future.
Trial registration: Seoul National University Hospital (SNUH) Institutional Review Board (IRB) (approval number: 2210-126-1371)
Publisher
Research Square Platform LLC
Reference23 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a cancer journal for clinicians 2021, 71(1):7–33.
2. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018;Hong S;Cancer Res Treat,2021
3. Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries;Sung WW;Sci Rep,2021
4. Moch HHP, Ulbright TM, Reuter VE. WHO classification of tumors of the urinary system and male genital organs. France: Lyon; 2016.
5. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review;Cimadamore A;Translational Androl Urol,2021